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Background: Pulmonary metastasectomy involves the
surgical removal of pulmonary nodules. It is a recognised
therapeutic modality for the treatment of metastatic disease.
There is no consensus as to the role of pulmonary
metastasectomy in squamous cell carcinoma of the head and
neck. The objective of this study was to determine whether,
in selected patients, resection of subsequent pulmonary
metastases prolongs survival in patients already treated for
head and neck squamous cell carcinoma and to identify
independent risk factors that influence 5-year survival of
patients undergoing pulmonary metastasectomy.
Methods: A systematic review of English and non-English
articles using MEDLINE (1950-present), EMBASE (1980-
present), NHS evidence and Cochrane databases. Search
terms included but were not limited to: squamous cell
carcinoma, pulmonary metastasectomy or resection, head
and neck cancer, malignancy or tumour. Studies examining
outcomes for patients with head and neck squamous cell
carcinoma who underwent pulmonary metastasectomy for
metachronous pulmonary metastases were included. Inde-
pendent data extraction of articles by two trained researchers
using predefined data fields was performed.
Results: Thirteen of 47 studies (all retrospective) fulfilled
eligibility criteria, with a total of 403 patients. In total, 11
papers reported 5-year survival rates (Kaplan–Meier) in 387
patients with head and neck squamous cell carcinoma
following pulmonary metastasectomy. Meta-analysis of
survival data showed an overall absolute 5-year survival rate
of 29.1% for patients undergoing pulmonary metastasecto-
my for metachronous metastases from head and neck
squamous cell carcinoma. Two papers reported significantly
worse 5-year survival rates in patients with oral head and
neck squamous cell carcinoma compared with other sites
(9.2% versus 32.4%, P < 0.001 and 15.4% versus 45.2%,
P = 0.01). Two papers reported that the presence of cervical
lymph node metastases at diagnosis of the primary tumour
significantly worsened 5-year survival rates following pul-
monary metastasectomy (13.8% (N+) versus 32% (N0)
P = 0.01 and 24% (N+) versus 60% (N0) P = 0.025). Other
significant poor prognostic factors included incomplete
pulmonary resection and the presence of multiple pulmo-
nary nodules.
Conclusions: This systematic review provides level 2a
evidence of the effectiveness of pulmonary metastasectomy
for metachronous pulmonary metastases from head and
neck squamous carcinoma, which may offer prolonged
survival for selected patients. Poor prognostic factors for
pulmonarymetastasectomy in this cohort of patients include
the presence of lymph nodemetastasis at the diagnosis of the
original tumour, squamous cell carcinoma of the oral cavity,
incomplete pulmonary resection and the presence of
multiple pulmonary nodules.
Reports of the incidence pulmonary metastases in patients
with squamous cell carcinoma of the head and neck range
from 1.6% to 40%.1,2 The lung is the most common site
of distant metastasis in head and neck squamous cell
carcinoma and accounts for 66% of all sites.3 When distant
metastases develop, the likelihood of long-term survival
becomes very low, and the disease is usually considered
incurable.4
Pulmonary metastasectomy involves the surgical removal
of metastatic nodules in the lung and is a recognised
treatment modality in a number of different cancers
including colorectal cancers, sarcoma, melanoma and renal
cell carcinoma.5 In general, a consensus has been reached
regarding eligibility for pulmonary metastasectomy: the
primary disease must be controlled; there should be no other
distant disease; complete resection of the pulmonary disease
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is possible with adequate pulmonary reserve; and there are
no other effective medical therapies.5 Pastorino et al.
retrospectively reviewed 5206 cases of pulmonary metasta-
sectomies for a number of different primary cancers from
the International Registry of Lung Metastases. They found
that the most important determinant of survival was
resectability. The overall 5-year survival for patients who
underwent complete resection was 36% compared to 13%
for patients who underwent incomplete resection.6
To date, there are no randomised controlled trials of
outcomes following pulmonarymetastasectomy in head and
neck squamous cell carcinoma, compared to either medical
therapy or observation.5 This is not surprising, considering
the dismal prognosis formetastatic head and neck squamous
cell carcinoma, it would be difficult to ethically justify
randomising a patient to non-surgical management over
pulmonary metastasectomy as non-surgical management is
invariably palliative, particularly if the patient was fit enough
to undergo surgery. Most retrospective reviews compare the
outcomes to historical data of the efficacy of chemotherapy
alone when used in a palliative setting. The 5-year survival
rate for chemotherapy for this indication is <5%.
Objectives
The aim of this study was to examine the survival rates of
patients with metastatic head and neck squamous cell
carcinoma who underwent pulmonary metastasectomy.
We undertook a systematic review of the literature that
assessed survival rates following this procedure in patients
with metastatic head and neck squamous cell carcinoma and
compared these with historical data for controls (patients
undergoing no treatment or non-surgical treatment).
Methods
Definitions
The histological appearance of pulmonary metastasis
following head and neck squamous cell carcinoma is
similar to the histological appearance of a second primary
lung cancer (SPLC). Differentiation between the two often
depends on clinical criteria including head and neck
squamous cell carcinoma tumour stage, disease-free inter-
val, number and site of the pulmonary lesions as well as
radiologic appearance.1 There is, therefore, a risk that
some tumours clinically diagnosed as metastatic may in
fact be second primaries, which potentially may have better
outcomes. Furthermore, patients with head and neck
squamous cell carcinoma are at increased risk of a second
lung primary; the relative risk of a second lung primary in
this context is three to six times that of the normal
population.1 For the purposes of this study, a pulmonary
metastasis following treatment for head and neck squa-
mous cell carcinoma is accepted as such if reported as
metastasis by clinical and histological criteria.
Ethical considerations
This article represents a systematic retrospective review of
previously published articles, and no patient identifiable
details are included.
Protocol and information sources
Methods of analysis and inclusion criteria were specified in
advance and documented in a protocol. Studies were
identified by searching electronic databases, and scanning
reference lists of articles. No limits were applied for language
or date of publication. The search strategy was applied to
Medline (1966-present), Embase (1980-present), NHS evi-
dence and Cochrane databases.We used the following search
terms to search all databases: ‘pulmonary’ or ‘thoracic’ or
‘lung’ AND ‘metastasectomy’ or ‘resection’ AND ‘cancer’
or ‘carcinoma’ or ‘squamous cell carcinoma’ or ‘malignancy’
or ‘tumour’ or ‘tumor’ AND ‘head and neck’ or ‘larynx’ or
‘pharynx’ or ‘oropharynx’ or ‘hypopharynx’ or ‘nasophar-
ynx’ or ‘oral’ or ‘tonsillar’ or ‘tongue’. The full electronic
search strategy is presented in Appendix 1.
Selection of articles
Eligibility assessment was performed independently in an
unbiased standardised manner by one reviewer. Abstracts
were screened using a priori criteria. The full articles of
the selected abstracts were then reviewed in detail for
eligibility by two trained reviewers. Eligibility criteria were
set before the start of the study. These were as follows: all
patients had locoregional control of the primary tumour at
the time of pulmonary metastasectomy, none had distant
metastases elsewhere, and all reported survival outcome
data on pulmonary metastasis from head and neck
squamous cell carcinoma, confirmed following histological
examination.
Inclusion criteria
Randomised control trials, prospective case series or case–
control studies examining outcomes following pulmonary
metastasectomy in patients with pulmonarymetastases from
head and neck squamous cell carcinoma were included, if
available. All surgical approaches to pulmonary metastasec-
tomy and both incomplete and complete resection were
included, as well as multiple or bilateral pulmonary nodules.
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No language or publication date restrictions were imposed.
Participants with metastatic pulmonary disease at the initial
diagnosis of head and neck squamous cell carcinoma were
excluded. Participants with additional non-pulmonary
metastases, uncontrolled primary sites and nodules found
not to be consistent with pulmonary metastases from head
and neck squamous cell carcinoma were also excluded.
Data collection
We developed a data extraction pro forma and carried out a
pilot test on 10 randomly selected included studies and
refined it accordingly. Data extraction was performed
independently and separately by two trained reviewers.
Disagreements were resolved by discussion between the two
reviewers, and then by discussion with the senior author.
Data were extracted from each included study on: charac-
teristics of study patients (including age at pulmonary
metastasectomy, gender, histology, site and stage of primary
tumour, treatment given for primary tumour); details of the
metastatic pulmonary lesion [including number, size and
site of nodules and disease-free interval (disease-free inter-
val)]; details of the pulmonary metastasectomy procedure
(including the operation performed, the approach, whether
the lesion was resectable and details of any additional
treatment); and outcome measures (including 1-, 3-, and
5-year survival rates).
Quality of studies
To ascertain the quality of eligible studies, the reviewers
evaluated the articles according to the following criteria: is the
study based on a representative sample selected from a
relevant population; do the authors explicitly state the criteria
for inclusion; was follow-up long enough to reach conclusions
regarding survival rates; were patients matched to controls;
were baseline characteristics reported on for head and neck
squamous cell carcinoma patients; and was data provided for
the nature and number of pulmonary nodules resected.
Outcome measures
The primary outcome measure was the absolute 5-year
survival rate of patients with squamous cell carcinoma of the
head and neck following pulmonary metastasectomy com-
pared with historical controls not undergoing surgery.
Statistical analysis
Weobtained an estimate of the between-study variance with a
random-effectsmeta-analysis. The square root of this number
is the estimated standarddeviationofunderlying effects across
studies. As we had relative measures of effect, the confidence
intervals were centred on the natural logarithm of the pooled
estimate and the limits exponentiated to obtain an interval on
the ratio scale. We tested for heterogeneity of the data using
the Cochran’s Q test and the I2 statistic.
Results
Study selection
The search of MEDLINE, EMBASE, NHS evidence and
Cochrane databases provided a total of 42 citations. A further
five papers were identified by checking the references of
relevant papers. After reviewing the abstracts of the papers,
27 of these 47 papers were excluded as they did notmeet the a
priori selection criteria. The full text of the remaining 20
papers was examined in detail. Thirteen papers met the
inclusion criteria, published between 1986 and 2011, and
were included in the review (see Fig. 1). The reasons for the
rejection of the seven others were as follows: the lung tumour
was not confirmed as metastasis from head and neck
squamous cell carcinoma (two articles); they described
non-head and neck squamous cell carcinoma primary
tumours (two articles); and they were inappropriate study
types in another three articles (two review articles, one
letter). Of the 13 studies, six also included patients with
primary tumours other than squamous cell carcinoma; these
patients were excluded from our analysis.
Participants
The studies included 403 patients. Only four studies reported
the mean age of the patients with head and neck squamous
cell carcinoma undergoing pulmonarymetastasectomy. This
is partially due to the fact that a proportion of the studies also
included patients with non-squamous cell carcinoma of the
head and neck; in these, data were reported for the whole
group of patients rather than the subgroup of patients with
head andneck squamous cell carcinoma. In studies reporting
age, the mean age of patients was 60 years (range of 21–
81 years). Ten studies with 320 patients reported the site of
the primary tumour. The most common site was the oral
cavity, including the oral tongue (96 patients, 30%), followed
by the larynx (88 patients, 27.5%), the hypopharynx (42
patients, 13%) and the oropharynx, including tonsil and base
of tongue (25 patients, 7.8%).
Study characteristics
All studies were retrospective reviews of either patient case
notes or of national databases. One study also included a
matched-pair analysis of patients operated on versus patients
210 E.R. Young et al.
© 2014 The Authors. Clinical Otolaryngology Published by John Wiley & Sons Ltd.  Clinical Otolaryngology 40, 208–218
not operated on. Further details of the studies are included in
Table 1. The quality of the studies was mainly moderate/
poor, and there was considerable risk of bias within studies
(see Table 2).
Interventions and outcomes
Complete data for disease-free interval, defined as the
duration from initial treatment of the primary tumour to
diagnosis of the pulmonarymetastasis, were only reported in
four studies. These reported median disease-free intervals of
12, 16, 21 and 36 months. Eight of the studies reported the
number of nodules resected. Of 286 patients, 197 (69%) had
a single nodule resected; the remaining 89 (31%) had
multiple nodules (up to a maximum of six) resected. Six
studies (227 patients) reported the type of operation
performed to resect the pulmonary nodule. The most
common operation was a lobectomy, performed in 116
(51%) patients (see Table 3). Five studies stated whether the
resection of the pulmonary metastasis was complete or
incomplete. Of these 216 patients, 159 (74%) were reported
to have had complete resection of their disease.
Overall survival following pulmonary metastasectomy for
metastatic head and neck squamous cell carcinoma
Absolute 5-year survival rates, extrapolated from Kaplan–
Meier survival rates, with 95% confidence intervals, follow-
ing pulmonary metastasectomy in patients with squamous
cell carcinoma of the head and neck are presented in Table 4.
Data were available for 5-year survival rates from 11 of the
13 studies, a total of 387 patients. Meta-analysis of survival
Literature search:
Databases: Medline, Embase, 
NHS evidence and Cochrane 
databases
Search results combined 
(n = 47)
Articles screened on basis of title 
and abstract
Excluded (n = 27)
Included (n = 20)
Manuscript review and 
application of inclusion criteria
Excluded (n = 7)
Lung tumour not confirmed as metastasis: 2
Non-head and neck primary cancer: 2
Letter of correspondence: 1
Review article: 2
Included (n = 13)
Fig. 1. Flow diagram of study selection.
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Table 1. Summary of included studies evaluating outcomes following pulmonarymetastasectomy (PM) for squamous cell carcinoma of the
head and neck
Source
No. of
participants
Mean age
at PM (if
reported)
Age range in
years at PM
(if reported) Type of study Setting
Site of
primary
tumour Outcomes
Geurts
(2009)1
8 61 37–73 Retrospective
case note
review
National
database, the
Netherlands
Larynx: 4
Hypopharynx: 1
Oropharynx: 1
Oral: 2
5-year
Kaplan–Meier
survival rates
Nibu
(1997)2
32 NR NR Retrospective
case note
review
Single Hospital,
Japan
Larynx: 5
Hypopharynx: 9
Oropharynx: 1
Oral: 13
Nasopharynx: 1
Sinonasal: 2
Other: 1
5-year
Kaplan–Meier
survival rates
Mochizuki
(2011)7
23 NR 28–72 Retrospective
case note
review
Two hospitals,
Japan
Oral (tongue) 1-,2-, and
3- year
Kaplan–Meier
survival rates
Haro
(2010)8
15 NR NR Retrospective case
note review
Single hospital,
Japan
Larynx: 4
Pharynx: 3
Oral: 5
Sinonasal: 3
5-year
Kaplan–Meier
survival rates
Chen
(2008)9
10 NR NR Retrospective case
note review
Single hospital,
Japan
Larynx: 1
Pharynx: 3
Oral: 6
1-,2-,3-
and 5-year
Kaplan–Meier
survival rates
Daiko
(2010)10
27 NR NR Retrospective case
note review
Single hospital,
Japan
Larynx: 6
Hypopharynx: 8
Oropharynx: 3
Oral: 7
Nasopharynx: 3
1- and 3-year
Kaplan–Meier
survival rates
Shiono
(2009)11
114 63 26–81 Retrospective
database
review
National
database, Japan
Larynx: 32
Hypopharynx:24
Oropharynx: 7
Oral: 27
Nasopharynx: 3
Sinonasal: 9
Salivary: 4
Other: 8
5-year
Kaplan–Meier
survival rates
Winter
(2008)12
55 NR NR Matched
pair-analysis
of patients
operated/
not operated
Single hospital,
Germany
NR 5-year
Kaplan–Meier
survival rates
Mazer
(1988)13
44 61.5 21–78 Retrospective
case note
review
Single hospital,
USA
Larynx: 11
Pharynx: 11
Tongue: 6
Tonsil: 7
Oral: 4
Other: 5
5-year
Kaplan–Meier
survival rates
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data showed an overall absolute 5-year survival rate of
29.1% (24.1–35.3, 95% confidence interval) for patients
undergoing pulmonary metastasectomy for metastasis from
squamous cell carcinoma of the head and neck. There was no
evidence of heterogeneity in this data (I2 = 0%, P = 0.462,
d.f. = 10).
Prognostic factors
Prognostic factors for survival following pulmonary metas-
tasectomy were also examined, including the site of the
primary tumour, disease-free interval, the completeness of
resection, age of the patient and whether there were
metastatic cervical lymph nodes present at the initial
diagnosis.
Site of the primary tumour. Two authors examined whether
the site of the primary tumour affected prognosis. Shiono
showed a significant difference between the 5-year survival of
patients with oral squamous cell carcinoma and non-oral
squamous cell carcinoma following pulmonary metastasec-
tomy (9.2% and 32.4%, respectively, risk ratio 3.67,
P < 0.001).11 This was supported by findings from Nibu
et al.2 who also showed significantly worse 5-year survival in
patients with oral squamous cell carcinoma compared to
non-oral squamous cell carcinoma (15.4% and 45.2%,
respectively, P = 0.01). Mochizuki et al.7 examined exclu-
sively oral tongue squamous cell carcinoma and also found
lower 5-year survival rates than other studies which included
a number of difference sites (see Table 4).
Primary cervical lymph node metastases. Shiono et al.
showed the presence of cervical lymph node metastases at
the diagnosis of the primary tumour was a significant
negative prognostic factor. Patients with cervical lymph
node metastasis at initial diagnosis were found to have a
5-year survival of 13.8% compared to survival of 32%
(P = 0.01) in patients with negative lymph nodes.11 This is
supported by Mazer et al.13 who found increased 5-year
survival rates in patients with no lymph node metastases
(60% versus 24%, P = 0.025).
Disease-free interval. Shiono et al. found significantly worse
prognosis when disease-free interval was <24 months.
Patients with disease-free interval <24 months had a 5-year
survival of 21% compared to patients with a disease-free
interval ofmore than 24 monthswhohad a 5-year survival of
40% (P = 0.044).11 This was supported by findings from
Mazer et al.13 who also showed a longer disease-free interval
equated with improved survival; patients with disease-free
interval 12–24 months had greater 5-year survival than
patients with disease-free interval of <12 months (83% and
20%, respectively,P < 0.005). Nibu et al.2 also showed that a
longer disease-free interval (13–24 months) correlated with
improved survival compared to a shorter disease-free
interval (0–12 months), although this was not statistically
significant (41.7% and 23.9% respectively, P = 0.16). Finley
et al.17 observed patients with a disease-free interval of
<1 year had a 5-year survival rate of 0%, compared with a
rate of 43% in patients with a disease-free interval between 1
and 2 years.
Completeness of resection. Shiono et al. showed that incom-
plete resection of the pulmonary nodule/s affected survival.
Patients with incomplete resection (n = 12) had a signifi-
cantly worse 5-year survival than patients with complete
Table 1. continued
Source
No. of
participants
Mean age
at PM (if
reported)
Age range in
years at PM
(if reported) Type of study Setting
Site of
primary
tumour Outcomes
Rendina
(1986)14
6 56.2 50–61 Retrospective
case note review
Single
hospital,
Italy
Larynx: 6 Survival time in
months
Wedman
(1996)15
10 NR NR Retrospective
case note review
Single hospital,
the Netherlands
NR NR
Liu
(1999)16
41 NR NR Retrospective
case-note review
Single Hospital,
USA
Larynx: 19
Pharynx: 13
Oral: 9
5-year
Kaplan–Meier
survival rates
Finley (1992)17 18 NR NR Retrospective case
note review
Single Hospital,
USA
NR 5-year
Kaplan–Meier
survival rates
NR, not reported.
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resection (n = 102) (25% and 26.7%, respectively, risk ratio
2.47, P = 0.037).11
Number of pulmonary metastases. Finley et al. demon-
strated that patients with multiple pulmonary nodules had
a poorer prognosis than those with a single nodule. Patients
with multiple metastases had a 0% 5-year survival compared
with a 50% survival in patients with a single metastasis
(P = 0.02).17 However, Shiono showed no survival advan-
tage in patients with a solitary metastasis compared to
multiple metastases (26% versus 27.3% 5-year survival,
P = 0.646).11
Age, gender and smoking history. Nibu et al. demonstrated
that younger patients at the time of pulmonary metastasec-
tomy had an improved outcome compared to older patients.
Patients between the ages of 31 and 55 years had a 5-year
survival rate of 48.6% compared to patients between the age
of 56 and 73 years, who had a 5-year survival rate of 10.3%
(P = 0.07).2 In the study conducted by Shiono et al.,11 men
had worse 5-year survival than women (22.9% and 41.3%),
although this difference was not significant (P = 0.355).
None of the studies examined smoking history as a
prognostic factor.
Discussion
We systematically reviewed and performed a meta-analysis
on retrospective case series examining absolute survival
rates following pulmonary metastasectomy and found an
absolute 5-year survival rate of 29.1% on meta-analysis.
Compared to published outcomes of alternative treatments
for pulmonary metastases from head and neck squamous
cell carcinoma, pulmonary metastasectomy appears to offer
a survival advantage. To date, there are no randomised
controlled trials that examine the efficacy of pulmonary
Table 2. Quality assessment of included studies
Author
Relevant
population?
Explicit
criteria for
inclusion?
Was follow-up
long enough?
Were patients
matched to
controls?
Were data provided
regarding the nature
and number of
nodules resected?
Geurts1 Yes Yes Yes, although one patient
lost to follow-up
after 30 months
No Yes
Nibu2 Yes Yes Yes – follow-up for at
least 3 years following
PM or until death
No Yes
Mochizuki7 Yes but oral tongue
SCC only
Yes Yes, one patient lost to
follow-up at 24 months,
all the rest until death
No Yes
Haro8 Yes Yes Not stated No No
Chen9 Yes Yes Yes No No
Daiko10 Yes Yes No – median follow-up
21 months
No No
Shiono11 Yes Yes Yes No Yes
Winter12 Yes Yes No – mean follow-up 29.4
months, patients alive at
last follow-up
Yes – matched paired
analysis of patients
operated/not operated on
No
Mazer13 Yes Yes No No Yes
Rendina14 Yes but laryngeal
SCC only
Yes No – follow-up only to a
maximum of 55 months
No Yes
Wedman15 Yes Yes Not stated No No
Liu16 Yes Yes No – follow-up to a median
of 38 months, patients alive
at last follow up
No Yes
Finley17 Yes No No – all patients followed up
until death, apart from seven
who were followed up to a
median of 24 months
No Yes
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metastasectomy. In all the studies we examined, patients
were selected for pulmonary metastasectomy based on their
fitness to survive major surgery and were therefore likely to
be fitter generally than patients not offered surgery.
Historically, the development of pulmonary metastases in
head and neck squamous cell carcinoma has heralded a very
poor prognosis, with treatment usually directed towards
palliation. Lefor et al.18 reviewed 15 patients with pulmo-
nary metastases from head and neck cancers (of mixed
histology) who did not undergo pulmonary metastasectomy
and found 1-year survival to be only 7%.Dennington et al.19
found only a 10% 2-year survival rate after the discovery of
pulmonary metastases in patients with head and neck
squamous cell carcinoma.Wedman et al.15 surveyed a group
of 117 patients with pulmonary metastases from cancer of
the head and neck who did not undergo pulmonary
metastasectomy and found them to have a 5-year survival
rate of only 4%, although they did not separately analyse
patients with squamous cell carcinoma. Winter et al.
performed a matched-pair analysis based on age, sex and
histology of the primary tumour, for survival of patients
operated on and those not operated on. Although their study
Table 3. Type of procedure, number of nodules resected and completeness of resection
Author
Total
number
of patients
Type of
procedure
Number of
nodules
resected Resection
Pneumonectomy Bilobectomy Lobectomy
Wedge
resection
Segmental
resection Single Multiple Complete Incomplete
Geurts1 8 0 0 3 5 0 4 4 NR NR
Nibu2 32 2 4 26 0 0 26 6 4 28
Mochizuki7 23 5 3 13 2 0 20 3 16 7
Haro8 15 NR NR NR NR NR NR NR NR NR
Chen9 10 NR NR NR NR NR NR NR NR NR
Daiko10 27 NR NR NR NR NR NR NR NR NR
Shiono11 114 5 0 62 37 10 84 30 102 12
Winter12 55 NR NR NR NR NR NR NR NR NR
Mazer13 44 1 0 9 34 0 28 16 NR NR
Rendina14 6 0 2 3 2* 0 5 1 6 0
Wedman15 10 NR NR NR NR NR NR NR NR NR
Liu16 41 NR NR NR NR NR 20 21 31 10
Finley17 18 NR NR NR NR NR 10 8 NR NR
NR, not reported.
*One patient underwent lobectomy and wedge resection in the same procedure.
Table 4. Absolute 5-year survival rates following pulmonary metastasectomy in patients with HNSCC
Author
Estimated absolute
5-year survival rate
Number of patients
in study Weights
95% confidence interval
Lower Upper
Geurts1 0.25 8 2 0.06 1.00
Nibu2 0.31 32 10 0.17 0.58
Mochizuki7 0.04 23 1 0.01 0.31
Haro8 0.27 15 4 0.10 0.71
Chen9 0.40 10 4 0.15 1.07
Daiko10 0.22 27 6 0.10 0.49
Shiono11 0.26 114 30 0.18 0.38
Winter12 0.20 55 11 0.11 0.36
Mazer13 0.43 44 19 0.28 0.68
Liu16 0.34 41 14 0.20 0.58
Finley17 0.28 18 5 0.12 0.67
Combined* 0.291† 387 – 0.241 0.353
*Two studies not included where data are not available. Decimal values round to the nearest number.
†Cochrans Q test for heterogeneity: Q = 9.761 on 10 degrees of freedom (P = 0.462).
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included cancers of mixed histology, they did show a
significant survival advantage in patients who underwent
pulmonary metastasectomy; patients undergoing surgery
had a median survival of 19.4 months compared to
5 months in patients not undergoing surgery (P < 0.001).12
Our systematic review has defined a number of variables
that suggest an improved prognosis following pulmonary
metastasectomy. These include younger age, female gender,
non-oral squamous cell carcinoma, no cervical lymph node
metastases on diagnosis of the primary tumour, a long
disease-free interval and complete resection of the pulmo-
nary metastasis. Squamous cell carcinoma of the oral cavity
predicts poorer outcome than other sites, although the
reasons for this are not clear. It is likely that the biological
aggressiveness of oral squamous cell carcinoma is responsi-
ble for this, rather than any other factor. It is also not clear
why cervical lymph node metastasis at initial diagnosis
should affect survival following pulmonary metastasectomy,
but may also indicate aggressiveness of the initial tumour.
The disease-free interval is possibly another indicator of
tumour aggressiveness.
Limitations
One major flaw of many of the studies is that it is often
difficult to distinguish between a metastatic pulmonary
nodule and a SPLC as discussed previously. Prior to 2005,
there was no reliable histological method for differentiation
between a head and neck squamous cell carcinoma metas-
tasis and a SPLC. Diagnosis of metastasis rather than a SPLC
is made by examining a number of criteria including
histological features, stage of the head and neck squamous
cell carcinoma, site and number of pulmonary lesions,
disease-free interval and radiologic appearance. Many
patients with head and neck squamous cell carcinoma have
a strong smoking history, which is also a risk factor for a
SPLC. Loss of heterozygosity analysis is a relatively new
molecular method of distinguishing between the two. A
report by Geurts et al.20 on loss of heterozygosity analysis
revealed that 18 of 44 cases of squamous cell lung lesions
which had been clinically interpreted as metastases from
head and neck cancers, were considered to be SPLC. It is
possible that some of the data presented relate to SPLC rather
than head and neck squamous cell carcinoma metastases.
However, in terms of prognosis following pulmonary
resection, differentiation between metastasis and a SPLC
may not carry any significance. Geurts et al.1 studied the
survival of patients following resection of molecularly
defined SPLC and compared this to survival of patients
following resection of molecularly defined head and neck
squamous cell carcinomametastasis and found no difference
in survival between the two. It would therefore seem that the
more important issue is whether they are deemed resectable
rather than whether they are metastasis or a SPLC.
Our study has several limitations, however. The meta-
analysis reported here combines data across these studies to
estimate survival rates withmore precision than is possible in
a single study, and there was no heterogeneity in our data.
The quality of the studies varied, and no study directly
compared outcomes following pulmonary metastasectomy
with patients not undergoing surgery in this specific
population of patients with head and neck squamous cell
carcinoma. There was a large variation in the publication
year of the studies and treatment protocols, follow-up and
surgical technique for both the primary tumour and
pulmonary metastasectomy may have changed over time.
Clinical implications
There is now recognition that HPV-positive head and neck
squamous cell carcinoma behaves in distinct ways compared
to HPV-negative head and neck squamous cell carcinoma
Leemans et al.21. Although HPV-positive head and neck
squamous cell carcinoma tumours are less likely to recur
locally, the rate of distant metastasis is similar to that of
HPV-negative head and neck squamous cell carcinoma
Huang et al.22 Huang et al. (2013) compared the natural
course of distant metastases following treatment for HPV-
positive oropharyngeal carcinoma and compared this to a
cohort of patients with metastasis from HPV-negative
oropharyngeal carcinoma. Whilst the rate of distant metas-
tasis was similar between the two groups, the survival rate
after distant metastasis was higher in the HPV-positive
group compared to theHPV-negative group (11% versus 4%
at 2 years, P = 0.02). However, the fact that these patients
were younger and less likely to smoke, most likely influenced
their rate of survival. As yet, there is no evidence to suggest
that HPV-positive metastases should be treated any differ-
ently from non-HPV metastases with regard to pulmonary
metastasectomy.
Our systematic review and meta-analysis demonstrate
that certain carefully selected patients with lung metastasis
following treatment for squamous cell carcinoma of the head
and neck may benefit from pulmonary metastasectomy. It is
important to appropriately identify those patients who
might benefit from more radical treatment, including
pulmonary metastasectomy.
Research implications
To date, there is little objective evidence regarding the
efficacy of pulmonary metastasectomy compared to non-
surgical treatment for metastatic head and neck squamous
cell carcinoma. This review consists of retrospective cohorts
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of patients treated between 1986 and 2011. With the
changing epidemiology of head and neck squamous cell
carcinoma, particularly the increase in HPV-positive
tumours, there is a need for randomised controlled trials
with tighter inclusion and exclusion criteria, possibly with a
molecular diagnosis of metastasis to rule out SPLC and
stratification by HPV status and primary tumour.
Conclusion
This systematic review and meta-analysis provide evidence
of the possible efficacy of metastasectomy for pulmonary
metastasis from squamous cell cancers of the head and neck.
Good prognostic factors include younger patients, female
gender with non-oral squamous cell carcinoma, long
disease-free interval, a single pulmonary nodule, complete
resection of the pulmonary metastasis and no nodal
metastasis at presentation. It shows evidence for a trend in
increased survival in patients undergoing pulmonary me-
tastasectomy compared to those who are not operated on.
Further research in this area is needed, preferably in the form
of randomised controlled trials.
Keypoints
• Pulmonary metastasectomy appears to offer an
appreciable survival advantage in carefully selected
patients.
• Good prognostic factors include younger patients,
female gender, non oral squamous cell carcinoma, a
long disease interval, no nodal metastasis at presenta-
tion and complete resection of the pulmonary
metastasis.
Conflict of interest
None to declare.
References
1 Geurts T.W., Balm A.J.M., van Velthuysen M.-L.F. et al. (2009)
Survival after surgical resection of pulmonary metastases and
second primary squamous cell lung carcinomas in head and neck
cancer. Head Neck 31, 220–226
2 Nibu K.-i., Nakagawa K., Kamata S.-e. et al. (1997) Surgical
treatment for pulmonary metastases of squamous cell carcinoma of
the head and neck. Am. J. Otolaryngol. 18, 391–395
3 Ferlito A., Shaha A.R., Silver C.E. et al. (2001) Incidence and site of
distant metastases from head and neck cancer. ORL J. Otorhinolar-
yngol. Relat. Spec. 63, 202–207
4 Younes R.N., Gross J.L., Silva J.F. et al. (1997) Surgical treatment of
lungmetastases of head and neck tumors. Am. J. Surg. 174, 499–502
5 Erhunmwunsee L. & D’Amico T.A. (2009) Surgical management of
pulmonary metastases. Ann. Thorac. Surg. 88, 2052–2060
6 Pastorino U., BuyseM., Friedel G. et al. (1997) Long-term results of
lung metastasectomy: prognostic analyses based on 5206 cases. J.
Thorac. Cardiovasc. Surg. 113, 37–49
7 Mochizuki T., Okumura S., Ishii G. et al. (2010) Surgical resection
for oral tongue cancer pulmonary metastases. Interact. Cardiovasc.
Thorac. Surg. 11, 56–59
8 Haro A., Yano T., Yoshida T. et al. (2010) Results of a surgical
resection of pulmonary metastasis from malignant head and neck
tumor. Interact. Cardiovasc. Thorac. Surg. 10, 700–703
9 Chen F., Sonobe M., Sato K. et al. (2008) Pulmonary resection for
metastatic head and neck cancer. World J. Surg. 32, 1657–1662
10 Daiko H., Nagai K., Yoshida J. et al. (2010) The role of pulmonary
resection in tumorsmetastatic from head and neck carcinomas. Jpn.
J. Clin. Oncol. 40, 639–644
11 Shiono S., Kawamura M., Sato T. et al. (2009) Pulmonary
metastasectomy for pulmonary metastases of head and neck
squamous cell carcinomas. Ann. Thorac. Surg. 88, 856–861
12 Winter H., Meimarakis G., Hoffmann G. et al. (2008) Does surgical
resection of pulmonarymetastases of head and neck cancer improve
survival? Ann. Surg. Oncol. 15, 2915–2926
13 Mazer T.M., Robbins K.T., McMurtrey M.J. et al. (1988) Resection
of pulmonary metastases from head and neck squamous cell
carcinoma. Am. J. Surg. 156, 238–242
14 Rendina E.A., de Vincentiis M., Primerano G. et al. (1986)
Pulmonary resection for metastatic laryngeal carcinoma. J. Thorac.
Cardiovasc. Surg. 92, 114–117
15 Wedman J., Balm A.J.M., Hart A.A.M. et al. (1996) Value of
resection of pulmonarymetastases in head and neck cancer patients.
Head Neck 18, 311–316
16 Liu D., Labow D.M., Dang N. et al. (1999) Pulmonary metastasec-
tomy for head and neck cancers. Ann. Surg. Oncol. 6, 572–578
17 Finley R.K. III, Verazin G.T., Driscoll D.L. et al. (1992) Results of
surgical resection of pulmonary metastases of squamous cell
carcinoma of the head and neck. Am. J. Surg. 164, 594–598
18 Lefor A.T., Bredenberg C.E., Kellman R.M. et al. (1986) Multiple
malignancies of the lung and head and neck. Second primary tumor
or metastasis? Arch. Surg. 121, 265–270
19 Dennington M.L., Carter D.R. & Meyers A.D. (1980) Distant
metastases in head and neck epidermoid carcinoma. Laryngoscope
90, 196–201
20 Geurts T.W., Nederlof P., van den Brekel M.W.M. et al. (2005)
Pulmonary squamous cell carcinoma: metastasis or second
primary? Clin. Cancer Res. 11, 6608–6614
21 Leemans C.R., Braakhuis B.J.M. & Brakenhoff R.H. (2010) The
molecular biologyofheadandneck cancer.Nat.Rev.Cancer11, 9–22
22 Huang S.H., Perez-Ordonez B., Weinreb I. et al. (2013) Natural
course of distant metastases following radiotherapy or chemora-
diotherapy in HPV-related oropharyngeal cancer. Oral. Oncology
49, 79–85
Appendix 1: Search strategy: MEDLINE
#1 Pulmonary [title/abstract] OR thoracic [title/abstract]
OR lung [title/abstract]
#2 Metastasectomy [title/abstract] OR resection [title/
abstract]
Pulmonary metastasectomy in treated head and neck cancer patients 217
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#3 Cancer [title/abstract] OR carcinoma [title/abstract]
OR squamous cell carcinoma [title/abstract] ORmalignancy
[title/abstract] OR tumor [title/abstract] OR tumour [title/
abstract]
#4 larynx [title/abstract] OR pharynx [title/abstract] OR
oropharynx [title/abstract] OR hypopharynx [title/abstract]
OR nasopharynx [title/abstract] OR oral [title/abstract] OR
tonsillar [title/abstract] OR tongue [title/abstract]
#5 head AND neck [title/abstract]
#6 #4 OR #5
#7 #1 AND #2 AND #3 AND #6
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